SCHEMBL770239

SCHEMBL770239

COc1ccccc1-n1cnc2cc(NCc3ccc(N(C)C)cc3)ccc21

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.80
MAPT P10636 7/20 0.80
TDP1 Q9NUW8 6/20 0.80
HPGD P15428 6/20 0.80
KDM4E B2RXH2 5/20 0.80
L3MBTL1 Q9Y468 3/20 0.80
KMT2A Q03164 6/20 0.67
MEN1 O00255 4/20 0.67
GAA P10253 3/20 0.67
GPR55 Q9Y2T6 2/20 0.67
LMNA P02545 5/20 0.65
SMN1; SMN2 Q16637 4/20 0.65
NPSR1 Q6W5P4 3/20 0.65
POLB P06746 2/20 0.65
HTT P42858 3/20 0.62
GFER P55789 2/20 0.62
KIT P10721 2/20 0.60
FLT3 P36888 2/20 0.60
TP53 P04637 1/20 0.60
ADRA2B P18089 5/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL770402 0.89 MAPT (1.00) ALDH1A1MAPTTDP1HPGDKDM4E
SCHEMBL783937 0.83 MAPT (0.86) ALDH1A1MAPTTDP1HPGDKDM4E
SCHEMBL769665 0.83 RAB9A (0.71) ALDH1A1MAPTTDP1HPGDKDM4E
SCHEMBL769271 0.80 MAPT (0.79) ALDH1A1MAPTTDP1HPGDKDM4E
SCHEMBL769090 0.75 KIT (0.77) ALDH1A1MAPTTDP1HPGDKDM4E
SCHEMBL13304989 0.73 ADRA2B (0.65) ALDH1A1MAPTTDP1HPGDKDM4E
SCHEMBL13305008 0.73 HPGD (0.67) ALDH1A1MAPTTDP1HPGDKDM4E
SCHEMBL770038 0.73 MAPT (0.72) ALDH1A1MAPTTDP1HPGDKDM4E
SCHEMBL13305002 0.72 L3MBTL1 (0.69) ALDH1A1MAPTTDP1HPGDKDM4E
SCHEMBL13305021 0.72 KIT (0.73) ALDH1A1MAPTTDP1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8629170-B2 Anti-viral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. (US) 2014-01-14 US claimed
EP-1988776-B1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION SIGA TECHNOLOGIES INC (US) 2012-08-08 EP claimed
US-20110172281-A1 Anti-Viral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2011-07-14 US claimed
US-7977365-B2 Antiviral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. (US) 2011-07-12 US claimed
EP-2291184-A2 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION Siga Technologies, Inc. (US) 2011-03-09 EP claimed
US-7872037-B2 Antiviral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. (US) 2011-01-18 US claimed
WO-2010036399-A2 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION SIGA TECHNOLOGIES, INC. (US) 2010-04-01 WO claimed
US-20080300265-A1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION SIGA TECHNOLOGIES INC. (US) 2008-12-04 US claimed
EP-1988776-A2 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION SIGA TECHNOLOGIES, INC. (US) 2008-11-12 EP claimed
US-20070254934-A1 Antiviral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. 2007-11-01 US claimed
WO-2007103111-A2 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION SIGA TECHNOLOGIES, INC. (US) 2007-09-13 WO claimed
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US disclosed
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US disclosed
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US disclosed
US-8629170-B2 Anti-viral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. (US) 2014-01-14 US disclosed
US-20080300265-A1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION SIGA TECHNOLOGIES INC. (US) 2008-12-04 US disclosed
US-20080300265-A1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION SIGA TECHNOLOGIES INC. (US) 2008-12-04 US disclosed
US-20080300265-A1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION SIGA TECHNOLOGIES INC. (US) 2008-12-04 US disclosed
US-20070254934-A1 Antiviral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. 2007-11-01 US disclosed
US-20070254934-A1 Antiviral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172281-A1 Anti-Viral Drugs for Treatment of Arenavirus Infection GK, GALK1, KLK7 ALDH1A1 4463/4885MAPT 923/4885TDP1 725/4885
US-20070254934-A1 Antiviral drugs for treatment of arenavirus infection GK, GALK1, GZMB ALDH1A1 4481/4885MAPT 1022/4885TDP1 634/4885
US-20080300265-A1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION GK, MAVS, ZC3HAV1 ALDH1A1 4399/4885MAPT 1158/4885TDP1 443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.